EUVIMEDEUVIMED entdecken
Crossref

Filgotinib Improves Experimental Pulmonary Fibrosis by Modulating JAK1/STAT3/SOCS3/IL‐17A Signalling

Yunying Lv, Guanghua Zhang, Dexin Kong, Wanglin Jiang

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Yunying Lv und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Binzhou Medical University, Yantai, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Triazoles, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Regulatory agencies in Europe and Japan have approved filgotinib, a selective JAK1 inhibitor, for use in treating rheumatoid arthritis, but its effect and mechanism of action in treating pulmonary fibrosis remain unclear.

Methods

We performed an in vivo investigation in rats on filgotinib's effect on pulmonary fibrosis resulting from the intratracheal infusion of bleomycin (BLM). Then, we focused on the mechanisms by which filgotinib inhibits experimentally induced pulmonary fibrosis in vitro by determining its effect on TGF‐β1‐induced proliferation of mouse lung fibroblasts.

Results

Continuous gavage of filgotinib at 20 mg/kg for 14 days elicited protective effects in the BLM‐induced rat experimental pulmonary fibrosis model, as reflected in changes in Hounsfield units as an indicator of overall pulmonary function and in the lung coefficient and lung microscopic pathology scores as indicators of gross pulmonary pathology. Protein expression levels of IL‐17A, phosphorylated tyrosine kinase (p‐JAK1), p‐STAT3 and cytokine signal transduction inhibitor 3 (SOCS3) were also changed. In in vitro studies, filgotinib at 1 μM reduced TGF‐β1‐induced fibroblast proliferation and produced lower levels of IL‐17A, p‐JAK1 and p‐STAT3, but higher SOCS3.

Conclusions

Filgotinib appeared to alleviate experimental pulmonary fibrosis by reducing fibroblast proliferation via inhibition of the JAK1/STAT3/SOCS3/IL‐17A pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisTriazolesPyridinesAnimalsJanus Kinase 1Signal TransductionSuppressor of Cytokine Signaling 3 ProteinBleomycinMiceSTAT3 Transcription FactorMaleRatsDisease Models, AnimalInterleukin-17FibroblastsCell ProliferationRats, Sprague-DawleyLungTransforming Growth Factor beta1

Stichwörter der Autor:innen

IL‐17AJAK1SOCS3STAT3filgotinibpulmonary fibrosis

Substanzen

Janus Kinase 1Suppressor of Cytokine Signaling 3 ProteinBleomycinSTAT3 Transcription FactorGLPG0634Interleukin-17TriazolesPyridinesJak1 protein, ratSocs3 protein, rat

Autor:innen und Institutionen

  • School of Pharmacy, Binzhou Medical University, Yantai, China.
  • Yantai Center for Food and Drug Control, Yantai, China.

Zitieren

APA

Lv, Y., Zhang, G., Kong, D., & Jiang, W. (2025). Filgotinib Improves Experimental Pulmonary Fibrosis by Modulating JAK1/STAT3/SOCS3/IL‐17A Signalling. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70012

Vancouver

Lv Y, Zhang G, Kong D, Jiang W. Filgotinib Improves Experimental Pulmonary Fibrosis by Modulating JAK1/STAT3/SOCS3/IL‐17A Signalling. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70012

BibTeX
@article{Lv2025,
  author = {Lv, Yunying and Zhang, Guanghua and Kong, Dexin and Jiang, Wanglin},
  title = {Filgotinib Improves Experimental Pulmonary Fibrosis by Modulating JAK1/STAT3/SOCS3/IL‐17A Signalling},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70012}
}
Kostenlos starten →